Sandoz has experienced a tough start to 2021 as pandemic-related pressures combined to drive down sales and profit in what management described as a “challenging” first quarter.
While parent company Novartis offered a relatively limited breakdown of Sandoz’ performance as it published first-quarter results today, it did reveal that turnover for the generics and biosimilars unit had tumbled by 9% as reported and by 13% at constant currencies to $2.307bn